This inventor holds 3 USPTO granted patents. Top assignee: Eisai Company, Limited. Active years: 1998-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ibaraki, JP (1998 - 2001)
- Tsukuba, JP (2002)
Company Filing History:
Years Active: 1998-2002
Title: ***Toshihiko Yamauchi: Pioneering Innovations in Nephritis and Graft Rejection Therapies***
Introduction
Toshihiko Yamauchi, an accomplished inventor based in Tsukuba, Japan, has made significant contributions to the field of medical science with his innovative approaches to treating nephritis and graft rejection reactions. With a total of three patents to his name, his work demonstrates a commitment to advancing therapeutic strategies through scientific research and development.
Latest Patents
Yamauchi's most recent patents focus on groundbreaking treatments utilizing retinoic acid agonists. The first patent addresses retinoic acid agonists as preventive and therapeutic agents for nephritis. The second patent outlines methods for preventing, inhibiting, or treating graft rejection reactions in graft-versus-host disease (GVHD) and organ transplantation. This invention highlights the use of retinoic acid receptor (RAR) agonists as an active ingredient, showcasing specific compounds such as 9-(4-methoxy-2,3,6-trimethylphenyl)-7,8-dimethylnona-2,4,6,8-tetraen-1-oic acid and various innovative benzoic acid derivatives.
Career Highlights
Yamauchi is a key innovator at Eisai Company, Limited, where he has dedicated his expertise to developing medical solutions that address complex health challenges. His work has not only resulted in valuable patents but has also contributed to the company's mission of improving patient outcomes across therapeutic areas.
Collaborations
Throughout his career, Toshihiko Yamauchi has collaborated with esteemed colleagues, including Akira Ishibashi and Naoki Tokuhara. These partnerships have fostered a rich environment of creativity and scientific inquiry, leading to the development of novel therapeutic agents and methods.
Conclusion
Toshihiko Yamauchi's contributions to medical innovation underscore the importance of research and collaboration in achieving breakthroughs in therapeutic treatments. His patents reflect a profound understanding of complex medical issues and the potential for retinoic acid agonists in improving patient care. As he continues to work at Eisai Company, Limited, the impact of his innovations is likely to resonate in the medical community for years to come.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile